journal
MENU ▼
Read by QxMD icon Read
search

Diabetes Technology & Therapeutics

journal
https://www.readbyqxmd.com/read/28722480/efficacy-and-safety-of-biosimilar-sar342434-insulin-lispro-in-adults-with-type-1-diabetes-also-using-insulin-glargine-sorella-1-study
#1
Satish Garg, Karin Wernicke-Panten, Maria Rojeski, Suzanne Pierre, Yvonne Kirchhein, Krystyna Jedynasty
BACKGROUND: SAR342434 is a biosimilar (follow-on) of insulin lispro-Humalog®. This study aimed to show similar efficacy, safety and immunogenicity of SAR342434 (SAR-Lis) versus insulin lispro-Humalog (Ly-Lis) in adult patients with type 1 diabetes (T1DM) treated with multiple daily injections while using basal insulin glargine (Lantus®; GLA100GLA-100). MATERIALS AND METHODS: SORELLA-1 was a randomized, open-label Phase 3 study (NCT02273180). Patients completing the 6-month main study continued on SAR-Lis or Ly-Lis, as randomized, for a 6-month safety extension...
July 19, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28704063/evaluation-of-accuracy-of-six-blood-glucose-monitoring-systems-and-modeling-of-possibly-related-insulin-dosing-errors
#2
Annette Baumstark, Nina Jendrike, Stefan Pleus, Cornelia Haug, Guido Freckmann
OBJECTIVE: Self-monitoring of blood glucose (BG) is an essential part of diabetes therapy. Accurate and reliable results from BG monitoring systems (BGMS) are important especially when they are used to calculate insulin doses. This study aimed at assessing system accuracy of BGMS and possibly related insulin dosing errors. RESEARCH DESIGN AND METHODS: System accuracy of six different BGMS (Accu-Chek(®) Aviva Nano, Accu-Chek Mobile, Accu-Chek Performa Nano, CONTOUR(®) NEXT LINK 2...
July 13, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28704062/flextouch-an-insulin-pen-injector-with-a-low-activation-force-across-different-insulin-formulations-needle-technologies-and-temperature-conditions
#3
Niels Gudiksen, Thibaud Hofstätter, Birgitte B Rønn, Thomas Sparre
FlexTouch® (Novo Nordisk A/S, Bagsvaerd, Denmark) is a pen-injector with a torque spring mechanism requiring a low activation force. This laboratory-based study compared the activation force of FlexTouch during the injection of insulin with different needles and at temperature conditions within the range at which the device is recommended for use. Using a tensile tester, activation force was measured at maximum dose settings for insulin detemir (100 U/mL) and insulin degludec (100 and 200 U/mL) at standard (23°C ± 5°C), cool (5°C ± 3°C), and warm (30°C ± 2°C) conditions...
July 13, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28700272/accuracy-of-a-fourth-generation-subcutaneous-continuous-glucose-sensor
#4
Mark P Christiansen, Satish K Garg, Ronald Brazg, Bruce W Bode, Timothy S Bailey, Robert H Slover, Ashley Sullivan, Suiying Huang, John Shin, Scott W Lee, Francine R Kaufman
BACKGROUND: This study evaluated the accuracy and performance of a fourth-generation subcutaneous glucose sensor (Guardian(™) Sensor 3) in the abdomen and arm. METHODS: Eighty-eight subjects (14-75 years of age, mean ± standard deviation [SD] of 42.0 ± 19.1 years) with type 1 or type 2 diabetes participated in the study. Subjects wore two sensors in the abdomen that were paired with either a MiniMed(™) 640G insulin pump, or an iPhone(®) or iPod(®) touch(®) running a glucose monitoring mobile application (Guardian Connect system) and a third sensor in the arm, which was connected to a glucose sensor recorder (GSR)...
July 12, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28700249/simulation-based-evaluation-of-dose-titration-algorithms-for-rapid-acting-insulin-in-subjects-with-type-2-diabetes-mellitus-inadequately-controlled-on-basal-insulin-and-oral-antihyperglycemic-medications
#5
Xiaosu Ma, Jenny Y Chien, Jennal Johnson, James Malone, Vikram Sinha
BACKGROUND: The purpose of this prospective, model-based simulation approach was to evaluate the impact of various rapid-acting mealtime insulin dose-titration algorithms on glycemic control (hemoglobin A1c [HbA1c]). METHODS: Seven stepwise, glucose-driven insulin dose-titration algorithms were evaluated with a model-based simulation approach by using insulin lispro. Pre-meal blood glucose readings were used to adjust insulin lispro doses. Two control dosing algorithms were included for comparison: no insulin lispro (basal insulin+metformin only) or insulin lispro with fixed doses without titration...
July 12, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28665142/targeting-one-hour-postmeal-glucose-is-it-time-for-a-paradigm-switch-in-diabetes-management
#6
Antonio Ceriello
In the management of diabetes, postprandial glycemia (PPG) is usually targeted 2 h after the start of meal. Recent evidences, however, suggest that the value of glycemia at 1 h during an oral glucose tolerance test (OGTT) is a stronger predictor for developing diabetes than the value at 2 h and that it is an independent risk factor for cardiovascular disease. Studies in cells, animals, and humans suggest that 1-h high glucose is a sufficient stimulus for increasing several cardiovascular risk factors, such as inflammation, thrombosis, and endothelial dysfunction, with oxidative stress generation as the possible pathogenetic factor...
June 30, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28605286/the-durability-of-basal-insulin-affects-day-to-day-glycemic-variability-assessed-by-continuous-glucose-monitoring-in-type-2-diabetes-patients-a-randomized-crossover-trial
#7
Hiroyuki Iuchi, Masaya Sakamoto, Daisuke Matsutani, Hirofumi Suzuki, Ryuzo Horiuchi, Kazunori Utsunomiya
BACKGROUND: Not only within-day glycemic variability but also day-to-day glycemic variability is a risk factor for diabetic patients. However, the ways of controlling day-to-day glycemic variability are unclear. We hypothesized that the durability of basal insulin plays an important role in controlling day-to-day glycemic variability in type 2 diabetes patients, and we therefore aimed to evaluate whether glargine U300, which exhibits prolonged absorption compared with glargine U100 but the same composition as glargine U100, would lead to improved day-to-day glycemic variability...
June 12, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28594566/severe-hypoglycemia-before-landing-in-a-patient-with-type-1-diabetes-using-sensor-augmented-pump-therapy
#8
Clara Viñals, Adriana Pané, Carmen Quirós, Marga Giménez, Ignacio Conget
No abstract text is available yet for this article.
June 8, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28581821/randomized-controlled-trial-of-technology-assisted-case-management-in-low-income-adults-with-type-2-diabetes
#9
Leonard E Egede, Joni S Williams, Delia C Voronca, Rebecca G Knapp, Jyotika K Fernandes
OBJECTIVE: To assess the efficacy of technology-assisted case management (TACM) with medication titration by nurses using guideline-based algorithms, under physician supervision in improving glycemic control in low-income rural adults with poorly controlled type 2 diabetes. RESEARCH DESIGN AND METHODS: Adults (aged ≥18 years) from the southeastern United States with hemoglobin A1c [HbA1c] ≥8% were randomized to TACM or usual care. Evidence-based guidelines were used to develop medication titration algorithms in conjunction with clinic physicians...
June 5, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28581818/effect-of-linagliptin-versus-metformin-on-glycemic-variability-in-patients-with-impaired-glucose-tolerance
#10
Tonatiuh González-Heredia, Diana M Hernández-Corona, Manuel González-Ortiz, Esperanza Martínez-Abundis
BACKGROUND: Impaired glucose tolerance (IGT) and glycemic variability may be associated with increased risk of micro- and macrovascular complications. The aim of this study was to assess the effect of linagliptin versus metformin on glycemic variability in patients with IGT. MATERIAL AND METHODS: A randomized, double-blind clinical trial with parallel groups was carried out in 16 adult patients with IGT, overweight or obesity. All patients signed an informed consent...
June 5, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28731823/maternal-fetal-outcomes-in-34-pregnant-women-with-type-1-diabetes-in-sensor-augmented-insulin-pump-therapy
#11
Ana María Gómez, Lisseth Fernanda Marín Carrillo, Carol M Arévalo Correa, Oscar Mauricio Muñoz Velandia, Martín Alonso Rondón Sepúlveda, Jaime Luis Silva Herrera, Diana Cristina Henao Carrillo
BACKGROUND: Pregnancy in women with type 1 diabetes (T1D) is associated with increased risk of maternal complications and neonatal morbidity and mortality. Optimizing glycemic control improves these outcomes. OBJECTIVE: To describe the experience of using sensor-augmented insulin pump therapy (SAPT) and SAPT + low-glucose suspension (LGS) on pregnant women with T1D, including neonatal and maternal outcomes. METHODS: A prospective observational study was conducted in women with T1D who started SAPT and SAPT + LGS before or during pregnancy at the San Ignacio University Hospital Diabetes Center in Bogotá, Colombia...
July 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28704065/re-castle-et-al-2017-diabetes-technol-ther-doi-10-1089-dia-2017-0012
#12
Francine R Kaufman, John Shin
No abstract text is available yet for this article.
July 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28686045/challenges-of-diabetes-management-in-toddlers
#13
Asma Deeb
Toddlers with type 1 diabetes have distinctive combination of challenges to their families and healthcare providers. A major factor is the difficulty in achieving metabolic control without risking hypoglycemia. The rising incidence of type 1 diabetes in toddlers increases the magnitude of the problem and creates a greater need for providing specialized service to cater for this age group's unique need. Type 1 has a specific disease nature in younger children and its clinical presentation mimics common childhood diseases...
July 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28686041/relevance-of-bolus-calculators-in-current-hybrid-closed-loop-systems
#14
Gregory P Forlenza
No abstract text is available yet for this article.
July 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28594575/bolus-calculator-reduces-hypoglycemia-in-the-short-term-and-fear-of-hypoglycemia-in-the-long-term-in-subjects-with-type-1-diabetes-cbmdi-study
#15
María Del Rosario Vallejo Mora, Mónica Carreira, María Teresa Anarte, Francisca Linares, Gabriel Olveira, Stella González Romero
BACKGROUND: In a previous study we demonstrated improvement in metabolic control and reduction in hypoglycemia in people with type 1 diabetes on multiple daily injections, after having used a bolus calculator for 4 months. OBJECTIVE: To demonstrate whether (1) extending its use (2) or introducing it in the control group, previously subjected to treatment intensification, could further improve metabolic control and related psychological issues. METHODS: After the previous clinical trial, in which the subjects were randomized either to treatment with the calculator or to control group for 4 months, both groups used the calculator during an additional 4-month period...
July 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28556672/faster-use-and-fewer-failures-with-needle-free-nasal-glucagon-versus-injectable-glucagon-in-severe-hypoglycemia-rescue-a-simulation-study
#16
Jean-François Yale, Hélène Dulude, Marc Egeth, Claude A Piché, Martin Lafontaine, Dolorès Carballo, Rebecca Margolies, Emily Dissinger, Adam R Shames, Nicole Kaplowitz, Michelle Xiaotian Zhang, Shuyu Zhang, Cristina B Guzman
BACKGROUND: During severe hypoglycemic episodes, people with diabetes depend on others to help with treatment. We compared needle-free nasal glucagon and commercially available injectable glucagon for ease of use by caregivers of people with diabetes and by others in treating simulated episodes of severe hypoglycemia. METHODS: Sixteen instructed caregivers and 15 noninstructed acquaintances administered nasal and injectable glucagon to manikins, simulating unconscious people with diabetes during severe hypoglycemia episodes...
July 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28537437/-it-is-definitely-a-game-changer-a-qualitative-study-of-experiences-with-in-home-overnight-closed-loop-technology-among-adults-with-type-1-diabetes
#17
Christel Hendrieckx, Lucinda A Poole, Amin Sharifi, Dilshani Jayawardene, Margaret M Loh, Jodie C Horsburgh, Leon A Bach, Peter G Colman, Kavita Kumareswaran, Alicia J Jenkins, Richard J MacIsaac, Glenn M Ward, Benyamin Grosman, Anirban Roy, David N O'Neal, Jane Speight
BACKGROUND: This qualitative study explored trial participants' experiences of four nights of in-home closed loop. METHODS: Sixteen adults with type 1 diabetes, who completed a randomized crossover trial, were interviewed after four consecutive nights of closed-loop. Interviews were audio recorded, transcribed, and analyzed with a coding framework developed to identify the main themes. RESULTS: Participants had a mean age of 42 ± 10 years, nine were women; mean diabetes duration was 27 ± 7 years, and all were using insulin pumps...
July 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28537427/overnight-counter-regulatory-hormone-levels-and-next-day-glycemia-in-adults-with-type-1-diabetes-during-closed-loop-insulin-delivery-versus-sensor-augmented-pump-with-low-glucose-suspend
#18
Anneke Graf, Glenn M Ward, Sara Vogrin, Vijaya Sundararajan, Amin Sharifi, Martin I De Bock, Dilshani Jayawardene, Margaret M Loh, Jodie C Horsburgh, Carolyn L Berthold, Nirubasini Paramalingam, Leon A Bach, Peter G Colman, Elizabeth A Davis, Benyamin Grosman, Alicia J Jenkins, Kavita Kumareswaran, Natalie Kurtz, Andrew Kyoong, Richard J MacIsaac, Anirban Roy, Timothy W Jones, David N O'Neal
No abstract text is available yet for this article.
July 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28530490/role-of-continuous-glucose-monitoring-in-clinical-trials-recommendations-on-reporting
#19
Oliver Schnell, Katharine Barnard, Richard Bergenstal, Emanuele Bosi, Satish Garg, Bruno Guerci, Thomas Haak, Irl B Hirsch, Linong Ji, Shashank R Joshi, Maarten Kamp, Lori Laffel, Chantal Mathieu, William H Polonsky, Frank Snoek, Philip Home
Thanks to significant improvements in the precision, accuracy, and usability of continuous glucose monitoring (CGM), its relevance in both ambulatory diabetes care and clinical research is increasing. In this study, we address the latter perspective and derive provisional reporting recommendations. CGM systems have been available since around the year 2000 and used primarily in people with type 1 diabetes. In contrast to self-measured glucose, CGM can provide continuous real-time measurement of glucose levels, alerts for hypoglycemia and hyperglycemia, and a detailed assessment of glycemic variability...
July 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28463010/behavioral-patterns-and-associations-with-glucose-control-during-12-week-randomized-free-living-clinical-trial-of-day-and-night-hybrid-closed-loop-insulin-delivery-in-adults-with-type-1-diabetes
#20
Ali Emami, Malgorzata E Willinska, Hood Thabit, Lalantha Leelarathna, Sara Hartnell, Sibylle Dellweg, Carsten Benesch, Julia K Mader, Manuel Holzer, Harald Kojzar, Thomas R Pieber, Sabine Arnolds, Mark L Evans, Roman Hovorka
OBJECTIVES: We evaluated patterns of meal intake, insulin bolus delivery, and fingerstick glucose measurements during hybrid closed-loop and sensor-augmented pump (SAP) therapy, including associations with glucose control. METHODS: Data were retrospectively analyzed from pump-treated adults with type 1 diabetes who underwent, in random order, 12 weeks free-living closed-loop (n = 32) and 12 weeks SAP (n = 33) periods. We quantified daily patterns of main meals, snacks, prandial insulin boluses, correction boluses, and fingerstick glucose measurements by analyzing data recorded on the study glucometer and on study insulin pump...
July 2017: Diabetes Technology & Therapeutics
journal
journal
34712
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"